AG
ALLO icon

Algert Global’s Allogene Therapeutics ALLO Stock Holding History

Algert Global’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$255K Sell
122,420
-341,560
-74% -$750K ﹤0.01% 1158
2026
Q1 		$1.13M Buy
463,980
+267,580
+136% +$536K 0.02% 839
2025
Q4 		$269K Buy
+196,400
New +$259K ﹤0.01% 1016
2024
Q3 		– Sell
-14,808
Closed -$34.5K – 1179
2024
Q2 		$34.5K Buy
+14,808
New +$43.7K ﹤0.01% 1462
2023
Q1 		– Sell
-13,125
Closed -$82.6K – 1128
2022
Q4 		$82.6K Hold
13,125
– – ﹤0.01% 1084
2022
Q3 		$142K Sell
13,125
-26,517
-67% -$360K 0.01% 1077
2022
Q2 		$452K Sell
39,642
-101,070
-72% -$897K 0.03% 794
2022
Q1 		$1.28M Buy
+140,712
New +$1.47M 0.08% 410
2021
Q4 		– Sell
-9,230
Closed -$237K – 955
2021
Q3 		$237K Buy
+9,230
New +$219K 0.03% 844

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Algert Global's ALLO Position: Q2 2026 in Review

Algert Global reduced its Allogene Therapeutics (ALLO) stake by 74% in Q2 2026, selling an estimated $750K and leaving 122,420 shares worth $255K. The position accounts for ﹤0.01% of the portfolio, ranked #1158.

Algert Global first reported a position in ALLO in Q3 2021 and has held it in 9 quarters since. The position peaked at $1.28M in Q1 2022. 210 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Algert Global held 122,420 shares of Allogene Therapeutics worth $255K as of Q2 2026.
  • Algert Global sold 341,560 Allogene Therapeutics shares in Q2 2026, an estimated $750K.
  • Allogene Therapeutics made up ﹤0.01% of Algert Global's portfolio in Q2 2026, its #1158 holding.
  • Algert Global first reported a position in Allogene Therapeutics in Q3 2021 and has held it in 9 quarters since.
  • Algert Global's Allogene Therapeutics position peaked at $1.28M in Q1 2022.
  • 210 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.